Article Text

PDF
CASE REPORT
Adalimumab-induced IgA nephropathy
  1. Aneesha Kaur Bhagat Singh1,2,
  2. Andrew Sujeevan Jeyaruban3,
  3. Gregory John Wilson4 and
  4. Dwarakanathan Ranganathan4,5
  1. 1 Internal Medicine, Royal Brisbane and Women’s Hospital, Herston, Queensland, Australia
  2. 2 Faculty of Medicine, University of Queensland, Herston, Queensland, Australia
  3. 3 Department of Medicine, Liverpool Hospital, NSW, Liverpool, New South Wales, Australia
  4. 4 Renal, Royal Brisbane and Women’s Hospital, Herston, Queensland, Australia
  5. 5 School of Medicine, Griffith University, Gold Coast, Queensland, Australia
  1. Correspondence to Dr Aneesha Kaur Bhagat Singh, aneeshakaur89{at}yahoo.com

Abstract

Immunoglobulin A nephropathy (IgAN) is the most commonly diagnosed glomerulonephritis worldwide. It is usually idiopathic and may be associated with many other diseases. Recently, biological agents including tumour necrosis factor alpha (TNFα) inhibitors have been identified as a potential cause for IgAN. We report the case of a 39-year-old woman who presented with renal dysfunction and visible haematuria. She had a background of Crohn’s disease (CD) and had been on adalimumab for 4 years following a right hemicolectomy. Subsequently, she underwent a renal biopsy that demonstrated IgAN and adalimumab was ceased. Following a flare in her CD, she was commenced on infliximab, which led to remission of the IgAN and CD. This is the first case to demonstrate the occurrence of IgAN as a complication of a TNFα inhibitor (adalimumab) that remained in remission despite the commencement of a second TNFα inhibitor (infliximab).

  • drug interactions
  • drugs: gastrointestinal system
  • inflammatory bowel disease
  • crohn’s disease
  • unwanted effects/adverse reactions
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors AKBS and ASJ contributed equally to this paper by acquiring results and writing this case report. GJW contributed by discussing the template and editing this paper. DR assisted in providing the idea for the case report, doing final edits and overlooking the case report.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.